Dupilumabe no tratamento de rinossinusite crônica com pólipo nasal em adolescente
Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps in adolescents
Caroline Pinto Pássaro; Sérgio Duarte Dortas-Junior; Nathássia da Rosa Paiva Bahiense Moreira; Fabiana Chagas da-Cruz; José Elabras-Filho; Priscila Novaes Ferraiolo; Solange Oliveira Rodrigues Valle
Resumo
O uso do anticorpo monoclonal dupilumabe em adultos tem possibilitado o controle da inflamação crônica, reduzindo significativamente o tamanho e a recorrência de novos pólipos, melhorando os sintomas nasais e, consequentemente, a qualidade de vida desses indivíduos. Relatamos o caso de uma adolescente que evidencia a eficácia de dupilumabe no tratamento da rinossinusite crônica com pólipo nasal.
Palavras-chave
Abstract
The use of the monoclonal antibody dupilumab in adults has allowed the control of chronic inflammation, significantly reducing the size and recurrence of new polyps, improving nasal symptoms, and, consequently, quality of life. We report a successful case of dupilumab use in an adolescent for the treatment of chronic rhinosinusitis with nasal polyps.
Keywords
References
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology. 2012;23:1-298.
2. Hox V, Bobic S, Callebaux I, Jorissen M, Hellings PW. Nasal obstruction and smell impairment in nasal polyp disease: correlation between objective and subjective parameters. Rhinology. 2010;48(4):426-32.
3. Ragab A, Clement P, Vincken W. Objective assessment of lower airway involvement in chronic rhinosinusitis. Am J Rhinol. 2004;18(1):15-21.
4. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373-7.
5. Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. Allergy Clin Immunol. 1977;59(1):17‑21.
6. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Jeremiah AA, Baroody FM, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6 Suppl 1:S22-S209.
7. Kosugi EM, Chen VG, Fonseca VMG, Cursino VMP, Mendes Neto JA, Gregório LC. Translation, cross-cultural adaptation and validation of SinoNasal Outcome Test (SNOT) - 22 to Brazilian Portuguese. Braz J Otorhinolaryngol. 2011;77(5):663-9.
8. Bachert C, Zhang N, Cavaliere C, Wiping W, Gevaert E, Krysco O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-39.
9. Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2):187-96.
10. Trimarchi M, Indelicato P, Vinciguerra A, Bussi M. Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial. Clin Case Rep. 2021;9:1428-32.
11. Shukla RH, Nemade SV, Shinde KJ. Comparison of visual analogue scale (VAS) and the Nasal Obstruction Symptom Evaluation (NOSE) score in evaluation of post septoplasty patients. World J Otorhinolaryngol Head Neck Surg. 2020;6(1):53-8.
12. Meltzer EO, Hamilos DL, Hadley JA, Donal MD, Lanza C, Nradley MD, et al. Rhinosinusitis: developing guidance for clinical trials. Otolaryngol Head Neck Surg. 2006;135(5 Supp):S31-S80.
13. Roxo JPF, Ponte EV, Ramos DCB, Pimentel L, D'Oliveira Júnior A, Cruz AA. Portuguese-language version of the Asthma Control Test. J Bras Pneumol. 2010;36(2):159-66.
14. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431-40.
15. Alobid I, Bernal-Sprekelsen M, Mullol J. Chronic rhinosinusitis and nasal polyps: The role of generic and specific questionnaires on assessing its impact on patient’s quality of life. Allergy Eur J Allergy Clin Immunol. 2008;63(10):1267-79.
16. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
17. Anselmo-Lima W, Tamashiro E, RomanoFR, Miyake MM Roithmann R, Kosugi EM, et al. Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil. Braz J Otorhinolaringol. 2021 [Article in press].
18. Sastre J, Dávila I. Dupilumab: A new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28:139‑50.
19. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016;315(5):469-79.
20. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-50.
Submitted date:
02/02/2022
Accepted date:
02/19/2022
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email